Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Treatment of Elderly Acute Myeloid Leukemia (AML) Patients with the Combination of Mitoxantrone and Cytarabine (MAC).

Theodoros Marinakis, MD, PhD, Athanasios G. Galanopoulos, MD, PhD, Athanasios Zomas, MD, Euridiki Michalis, MD, George Gortzolidis, MD, Anastasia Tsakiridou, MD, Vasilios Xanthopoulos, MD, George Theodoropoulos, MD, Helen Goumakou, MD, Maria Georgiakaki, MD, Vasiliki Grigoraki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4624.

https://doi.org/10.1182/blood.V106.11.4624.4624

Published: 2005

Journal Articles

Clinical Outcome of the Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with the Hyper-CVAD Protocol.

Theodoros Marinakis, MD, PhD, Athanasios Zomas, MD, Athanasios G. Galanopoulos, MD, PhD, Eurydiki Michalis, MD, George Gortzolidis, MD, Ioannis Tsourveloudis, MD, Ioanna Savvidou, MD, George Theodoropoulos, MD, Stephanos Papadhimitriou, MD, George Paterakis, MD, Vasiliki Grigoraki, MD, Maria Georgiakaki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4588.

https://doi.org/10.1182/blood.V106.11.4588.4588

Published: 2005

Journal Articles

A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Athanasios G. Galanopoulos, MD, PhD, Anastasia Tsakiridou, MD, Eurydiki Michalis, MD, Theodoros Marinakis, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Vasilios Xanthopoulos, MD, Ioanna Savvidou, MD, George Theodoropoulos, MD, Vasiliki Grigoraki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4740.

https://doi.org/10.1182/blood.V106.11.4740.4740

Published: 2005

Journal Articles

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Athanasios Anagnostopoulos, MD, Steven P. Treon, MD, Konstantinos Zervas, MD, Andrew Branagan, MD, Dimitra Gika, Athanasios Zomas, MD, Marie Christine Kyrtsonis, MD, Amalia Vassou, MD, Nikolaos Anagnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3485.

https://doi.org/10.1182/blood.V106.11.3485.3485

Published: 2005

Journal Articles

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

Athanasios Anagnostopoulos, MD, Konstantinos Zervas, MD, Evangelos Terpos, MD, Marie Christine Kyrtsonis, MD, Argyris Symeonidis, MD, Dimitra Gika, Konstantinos Bourantas, MD, Athanasios Zomas, MD, Nikolaos Angnostopoulos, MD, Gerasimos Pangalis, MD, Meletios A. Dimopoulos, MD

Blood (2005) 106 (11): 3415.

https://doi.org/10.1182/blood.V106.11.3415.3415

Published: 2005

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Evangelos Terpos, MD, PhD, Athanasios Anagnostopoulos, MD, PhD, Efstathios Kastritis, MD, Athanasios Zomas, MD, Christos Poziopoulos, MD, Nikolaos Anagnostopoulos, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 363.

https://doi.org/10.1182/blood.V106.11.363.363

Published: 2005

Journal Articles

Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).

Athanasios G. Galanopoulos, MD, PhD, Stephanos Papadhimitriou, MD, Ioannis Tsourveloudis, MD, Evridiki Michalis, MD, Theodoros Marinakis, MD, PhD, Anastasia Tsakiridou, MD, Ioanna Savvidou, MD, Vasilios Xanthopoulos, MD, George Theodoropoulos, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Maria Georgiakaki, MD, Nikolaos I. Anagnostopoulos, MD, PhD

Blood (2005) 106 (11): 4907.

https://doi.org/10.1182/blood.V106.11.4907.4907

Published: 2005

Journal Articles

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Meletios A. Dimopoulos, MD, Panagiotis Repoussis, MD, Evangelos Terpos, MD, Maria Christina Kyrtsonis, MD, Athanasios Zomas, MD, Eirini Katodritou, MD, Souzana Delibasi, MD, Amalia Vassou, MD, Athanasios Anagnostopoulos, MD, Anastasia Pouli, MD, Konstantinos Zervas, MD, Dimitrios Margaritis, MD, Nikolaos Anagnostopoulos, MD, Alice G. Maniatis, MD

Blood (2004) 104 (11): 1482.

https://doi.org/10.1182/blood.V104.11.1482.1482

Published: 2004

Journal Articles

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Meletios A. Dimopoulos, MD, Maria Christina Kyrtsonis, MD, Constantinos Tsatalas, MD, Garyfallia Kokkini, MD, Panagiotis Repoussis, MD, Athanasios Zomas, MD, Argiris Symeonidis, MD, Evridiki Michali, MD, Athanasios Anagnostopoulos, MD, Nikolaos Anagnostopoulos, MD, Theophanis Economopoulos, MD, Gerasimos Pangalis, MD

Blood (2004) 104 (11): 752.

https://doi.org/10.1182/blood.V104.11.752.752

Published: 2004

Journal Articles

Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Athanasios G. Galanopoulos, MD, PhD, Anastasia Tsakiridou, MD, Eurydiki Michalis, MD, Theodoros Marinakis, MD, George Gortzolidis, MD, Athanasios Zomas, MD, Ioannis Tsourveloudis, MD, Maria Tsirogianni, MD, Stephanos Papadhimitriou, MD, Elpiniki Kritikou-Griva, MD, Nikolaos I. Anagnostopoulos, MD

Blood (2004) 104 (11): 4825.

https://doi.org/10.1182/blood.V104.11.4825.4825

Published: 2004

NARROW

Treatment of Elderly Acute Myeloid Leukemia (AML) Patients with the Combination of Mitoxantrone and Cytarabine (MAC).

Clinical Outcome of the Treatment of Adult Acute Lymphoblastic Leukemia (ALL) with the Hyper-CVAD Protocol.

A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Predictive Factors for Response and Progression after Treatment with Rituximab in Previously Untreated Patients with Waldenstrom’s Macroglobulinemia (WM).

Prognostic Value of Serum β2-Microglobulin in Patients with Waldenstrom’s Macroglobulinemia Requiring Treatment.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Deletion of Tumor Suppressor Genes (TSGS) in Patients with Myelodysplastic Syndrome (MDS).

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only